1. Received prior imatinib therapy<br/><br/>          2. Received prior dasatinib therapy<br/><br/>          3. Received prior nilotinib therapy<br/><br/>          4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or<br/>             radiation therapy with the exception of anagrelide or hydroxyurea<br/><br/>          5. Major surgery within 28 days prior to initiating therapy<br/><br/>          6. History of bleeding disorder unrelated to CML<br/><br/>          7. History of acute pancreatitis within 1 year of study or history of chronic<br/>             pancreatitis<br/><br/>          8. History of alcohol abuse<br/><br/>          9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)<br/><br/>         10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically<br/>             including, but not restricted to:<br/><br/>               1. Myocardial infarction, within 6 months prior to randomization<br/><br/>               2. Unstable angina within 6 months prior to randomization<br/><br/>               3. Congestive heart failure within 6 months prior to randomization<br/><br/>               4. History of clinically significant (as determined by the treating physician)<br/>                  atrial arrhythmia or any ventricular arrhythmia<br/><br/>               5. Any history of ventricular arrhythmia<br/><br/>               6. Cerebrovascular accident or transient ischemic attack within 6 months prior to<br/>                  randomization<br/><br/>               7. Any history of peripheral arterial occlusive disease requiring revascularization<br/><br/>               8. Any  history of venous thromboembolism including deep venous thrombosis or<br/>                  pulmonary embolism<br/><br/>         11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).<br/>             Patients with hypertension should be under treatment on study entry to effect blood<br/>             pressure control<br/><br/>         12. Taking medications that are known to be associated with Torsades de Pointes<br/><br/>         13. Ongoing or active infection.  The requirement for intravenous (IV) antibiotics is<br/>             considered active infection<br/><br/>         14. Known history of human immunodeficiency virus (HIV).  Testing is not required in the<br/>             absence of history<br/><br/>         15. Pregnant or breastfeeding<br/><br/>         16. Malabsorption syndrome or other gastrointestinal illness that could affect oral<br/>             absorption of study drugs<br/><br/>         17. Diagnosed with or received anticancer therapy for another primary malignancy within 3<br/>             years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)<br/><br/>         18. Any condition or illness that, in the opinion of the Investigator, would compromise<br/>             patient safety or interfere with the evaluation of the drug<br/>